Management of Heart Failure with Hypertension and Diabetes

Immediate Pharmacologic Management

The American College of Cardiology recommends initiating guideline-directed medical therapy (GDMT) consisting of an ACE inhibitor, beta-blocker, diuretic, and aggressive management of non-compliance through structured follow-up programs for patients with heart failure and hypertension 1, 2
The American Heart Association suggests starting all four medication classes simultaneously for patients with symptomatic heart failure, including an ACE inhibitor, beta-blocker, diuretic, and potentially an aldosterone receptor antagonist 1, 2, 3
The American College of Cardiology recommends titrating ACE inhibitors to target doses as tolerated, and substituting with an ARB if ACE inhibitors are not tolerated due to cough or angioedema 1, 2
Beta-blockers, such as carvedilol, metoprolol succinate, or bisoprolol, should be added regardless of blood pressure, as they reduce mortality in heart failure patients even when added to ACE inhibitors 1, 2

The American College of Cardiology recommends targeting a systolic blood pressure of 130 mmHg, but not less than 120 mmHg, to avoid worsening cardiac output 1, 3

The American Diabetes Association recommends maintaining glycemic control, as diabetes is a major risk factor for heart failure progression 5, 6
The American College of Cardiology suggests considering SGLT2 inhibitors, which improve outcomes in both HFrEF and HFpEF 3

The American College of Cardiology recommends avoiding non-dihydropyridine calcium channel blockers, moxonidine, clonidine, and alpha-blockers, as they can worsen heart failure 1, 3

The American College of Cardiology recommends implementing close supervision between physician visits, daily weight monitoring, patient education, and surveillance systems to detect early decompensation 7, 8

The American College of Cardiology recommends initial laboratory evaluation, including complete blood count, comprehensive metabolic panel, fasting lipid profile, liver function tests, thyroid-stimulating hormone, and HbA1c for diabetes monitoring 9, 10
The American College of Cardiology suggests imaging studies, including echocardiography with Doppler, repeat chest X-ray, and 12-lead ECG, to assess ejection fraction, chamber size, wall thickness, and valve function 5, 9, 10

The American College of Cardiology recommends starting low and going slow with ACE inhibitors and beta-blockers, uptitrating to target doses proven in clinical trials, and adjusting diuretics to achieve and maintain euvolemic state 2, 7, 8

The American College of Cardiology recommends cardiology follow-up within 1-2 weeks of discharge, enrollment in a heart failure disease management program, and home health services for medication supervision and weight monitoring 2, 7, 8